GBT.PA Guerbet SA EURONEXT jumps 10.00% intraday at €9.24: watch forecast and targets

GBT.PA stock led intraday gainers on 19 Mar 2026 after a 10.00% rise to €9.24 on EURONEXT, backed by a volume uptick to 13,540 shares. Traders priced a recovery versus the 50-day average of €13.27 and the 200-day average of €16.76. We cover why Guerbet SA (GBT.PA) moved, how fundamentals and technicals line up, and what model-based targets suggest for investors watching Healthcare names in Europe.

Intraday price action and market context

One clear fact: Guerbet SA (GBT.PA) traded between €9.04 and €9.29 intraday on 19 Mar 2026. Volume of 13,540 topped the average volume of 13,006, giving a relative volume of 1.96, which supports the intraday gain. The move stands against Healthcare sector YTD strength of 0.75%, and highlights active short-term interest in Medical – Devices names on EURONEXT.

GBT.PA stock fundamentals and valuation

Guerbet reports a market cap of €117,442,429 and negative earnings per share of -8.93, producing a PE of -1.04. Price-to-book is 0.31 and price-to-sales is 0.15, showing deep value on accounting metrics. The balance sheet shows book value per share €29.44 and cash per share €3.96, while debt-to-equity stands near 1.06, a clear structural risk for the stock.

Meyka AI rates GBT.PA with a score out of 100 and forecast

Meyka AI rates GBT.PA with a score out of 100: 66.63 (Grade B, HOLD). This grade factors in S&P 500 and sector comparison, financial growth, key metrics, forecasts, and analyst consensus. Meyka AI’s forecast model projects a yearly price of €18.13, implying +96.15% from the current €9.24. Forecasts are model-based projections and not guarantees.

Technical outlook for GBT.PA stock

Technicals show oversold signals: RSI 11.48 and Stochastic %K 13.04, suggesting strong downward momentum recently. MACD is negative with histogram -0.26, and Bollinger lower band sits at €10.92, indicating price below recent volatility bands. Traders should note the 50-day average €13.27 and 200-day average €16.76 as resistance levels on any rebound.

Risks, catalysts and sector comparison

Key risks include negative EPS and interest coverage -24.26, plus a long days-of-inventory figure 322.15 days. Catalysts that could lift the stock are improved margins, clearer guidance at the next earnings announcement on 2026-09-15, or stronger adoption of Guerbet’s digital solutions. Compared with Healthcare peers, Guerbet’s price-to-book 0.31 is low versus the sector average, highlighting valuation risk and opportunity.

Trading strategy and analyst view

For intraday and short-term traders, watch volume and the €9.29 intraday high as a first breakout level. Analysts’ consensus includes a company rating of C (Sell) as of 2026-03-18, while DCF inputs show a contrasting Strong Buy view. We suggest a staged approach: small positions on confirmed volume-backed breakouts, strict stops below €8.01 year low, and use targets below to size positions.

Final Thoughts

GBT.PA stock moved sharply intraday to €9.24 on 19 Mar 2026, led by higher-than-average volume and oversold technical reads. Fundamentals show low valuation metrics—price-to-book 0.31 and price-to-sales 0.15—but also persistent earnings losses and leverage. Meyka AI’s forecast model projects €18.13 for the year, implying +96.15% upside from the current price, while a conservative near-term target of €12.00 implies +29.87% and a bull target at the 52-week high €27.60 implies +198.70%. These figures frame scenarios, not guarantees. Short-term traders should follow volume and resistance at €13.27 and €16.76. Longer-term investors must weigh cash generation against operational headwinds and sector dynamics in Healthcare on EURONEXT. Meyka AI provides this as AI-powered market analysis, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.